ECSP21079184A - Anticuerpos contra amiloide-beta con piroglutamato y usos de estos - Google Patents

Anticuerpos contra amiloide-beta con piroglutamato y usos de estos

Info

Publication number
ECSP21079184A
ECSP21079184A ECSENADI202179184A ECDI202179184A ECSP21079184A EC SP21079184 A ECSP21079184 A EC SP21079184A EC SENADI202179184 A ECSENADI202179184 A EC SENADI202179184A EC DI202179184 A ECDI202179184 A EC DI202179184A EC SP21079184 A ECSP21079184 A EC SP21079184A
Authority
EC
Ecuador
Prior art keywords
amyloid
pyroglutamate
antigen
binding fragments
beta antibodies
Prior art date
Application number
ECSENADI202179184A
Other languages
English (en)
Inventor
Marc Mercken
Wilson Edwards
Jinquan Luo
Broeck Bianca Van
Chichi Huang
Porte Sherry La
Sanjaya Singh
Rajkumar Ganesan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP21079184A publication Critical patent/ECSP21079184A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona anticuerpos o fragmentos de unión al antígeno de estos que se unen a Aβ 3pE y métodos para elaborar y usar los anticuerpos o fragmentos de unión al antígeno de estos, que incluyen el uso para formulaciones, administración y kits. El anticuerpo y fragmentos de unión al antígeno de este y los métodos descritos son útiles para el diagnóstico, pronóstico y tratamiento de la enfermedad de Alzheimer u otras enfermedades relacionadas con el amiloide β.
ECSENADI202179184A 2019-03-26 2021-10-26 Anticuerpos contra amiloide-beta con piroglutamato y usos de estos ECSP21079184A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962823785P 2019-03-26 2019-03-26

Publications (1)

Publication Number Publication Date
ECSP21079184A true ECSP21079184A (es) 2021-11-30

Family

ID=70008544

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202179184A ECSP21079184A (es) 2019-03-26 2021-10-26 Anticuerpos contra amiloide-beta con piroglutamato y usos de estos

Country Status (22)

Country Link
US (4) US20220177560A1 (es)
EP (1) EP3946603A1 (es)
JP (2) JP7617848B2 (es)
KR (1) KR20210143858A (es)
CN (2) CN113891746B (es)
AU (1) AU2020245031B2 (es)
BR (1) BR112021019107A2 (es)
CA (1) CA3134785A1 (es)
CL (2) CL2021002473A1 (es)
CO (1) CO2021014028A2 (es)
CR (1) CR20210492A (es)
DO (1) DOP2021000199A (es)
EA (1) EA202192606A1 (es)
EC (1) ECSP21079184A (es)
IL (1) IL286634A (es)
JO (1) JOP20210265A1 (es)
MA (1) MA55491A (es)
MX (1) MX2021011715A (es)
PE (1) PE20212266A1 (es)
PH (1) PH12021552334A1 (es)
SG (1) SG11202110504XA (es)
WO (1) WO2020193644A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
SG11202110504XA (en) * 2019-03-26 2021-10-28 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
IL312360A (en) * 2021-10-28 2024-06-01 Abbvie Inc Anti-amyloid beta antibodies and methods of using them
CA3254442A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv MULTISPECIFIC ANTIBODIES AND THEIR USES
TW202400636A (zh) 2022-03-11 2024-01-01 比利時商健生藥品公司 多特異性抗體及其用途(一)
EP4490185A1 (en) 2022-03-11 2025-01-15 JANSSEN Pharmaceutica NV Multispecific antibodies and uses thereof
WO2024133925A1 (en) 2022-12-22 2024-06-27 Bioarctic Ab Antibody which binds to abetape3
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule
CN118459582B (zh) * 2024-07-11 2024-11-15 苏州近岸蛋白质科技股份有限公司 一种抗焦谷氨酸修饰的β淀粉样蛋白抗体及其用途
WO2026158687A1 (zh) * 2025-01-27 2026-07-30 甘李药业股份有限公司 抗Aβ抗体及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US9907485B2 (en) 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
WO2010004434A2 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
KR101706789B1 (ko) 2008-07-21 2017-02-14 프로비오드룩 아게 진단용 항체 검사법
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
AU2011221226A1 (en) * 2010-02-23 2012-08-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8795664B2 (en) * 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
WO2012021475A2 (en) 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SI3339323T1 (sl) * 2010-08-12 2019-12-31 Eli Lilly And Company Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
WO2015191825A1 (en) 2014-06-13 2015-12-17 Biogen Ma Inc. Methods for the detection and measurement of amyloid beta in biological samples
EA201790336A1 (ru) * 2014-08-07 2017-06-30 Новартис Аг Антитела к ангиопоэтинподобному белку 4 и способы применения
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
NZ739181A (en) 2015-07-16 2023-05-26 Vivoryon Therapeutics N V Anti-pyroglutamated amyloid beta humanized antibodies
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
AR107774A1 (es) 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
EP3249388A1 (en) 2016-05-23 2017-11-29 Raman Health Technologies, S.L Method for diagnosing alzheimer´s disease
MX2018015022A (es) 2016-06-07 2019-08-14 Biogen Int Neuroscience Gmbh Métodos para el tratamiento de la enfermedad de alzheimer.
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
AR110470A1 (es) 2016-10-21 2019-04-03 Lilly Co Eli Terapia de combinación para tratar la enfermedad de alzheimer
TW201827467A (zh) * 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
TWI789644B (zh) 2017-04-20 2023-01-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
SG11201910066QA (en) * 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
MD3672631T3 (ro) 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
JP7465272B2 (ja) * 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
SG11202110504XA (en) * 2019-03-26 2021-10-28 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF

Also Published As

Publication number Publication date
SG11202110504XA (en) 2021-10-28
CN113891746A (zh) 2022-01-04
CN113891746B (zh) 2025-05-06
CN120468431A (zh) 2025-08-12
KR20210143858A (ko) 2021-11-29
CR20210492A (es) 2021-11-19
DOP2021000199A (es) 2022-07-15
US20220177560A1 (en) 2022-06-09
EP3946603A1 (en) 2022-02-09
US11236155B2 (en) 2022-02-01
WO2020193644A1 (en) 2020-10-01
CA3134785A1 (en) 2020-10-01
US20220106387A1 (en) 2022-04-07
MA55491A (fr) 2022-02-09
CO2021014028A2 (es) 2021-10-29
JP7837375B2 (ja) 2026-03-30
AU2020245031B2 (en) 2026-04-09
CL2022002670A1 (es) 2023-03-31
PE20212266A1 (es) 2021-11-30
IL286634A (en) 2021-10-31
CL2021002473A1 (es) 2022-04-22
JP2025000645A (ja) 2025-01-07
PH12021552334A1 (en) 2022-07-04
EA202192606A1 (ru) 2022-01-24
JP7617848B2 (ja) 2025-01-20
US20250320286A1 (en) 2025-10-16
MX2021011715A (es) 2021-12-10
BR112021019107A2 (pt) 2021-11-30
AU2020245031A1 (en) 2021-10-21
US20200308261A1 (en) 2020-10-01
JOP20210265A1 (ar) 2023-01-30
JP2022526528A (ja) 2022-05-25

Similar Documents

Publication Publication Date Title
DOP2021000199A (es) ANTICUERPOS CONTRA AMILOIDE-ß CON PIROGLUTAMATO Y USOS DE ESTOS
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
CL2019002922A1 (es) Anticuerpos anti-péptido beta amiloide n3pglu y sus usos.
CL2021002008A1 (es) Proteinas de unión de antígeno del receptor gamma anti-il2.
DOP2006000099A (es) Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2023011121A (es) Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos.
ECSP20063690A (es) Anticuerpos
ECSP066294A (es) Un conjugado citotóxico ca6 antígeno-específico y métodos para utilizar el mismo
MX2020006736A (es) Anticuerpos monoclonales y metodos para utilizar los mismos.
PE20211792A1 (es) Anticuerpos monoclonales que se unen especificamene a la region beta de la familia trbv-9 del receptor de celulas t humano, y los metodos para su uso
CO2020014681A2 (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
MX2021015501A (es) Anticuerpos y metodos de uso.
MX2021003119A (es) Anticuerpos anti-klrg1.
PE20230602A1 (es) Anticuerpos anti-sea de muc1
DOP2022000058A (es) Anticuerpos contra el factor de las células madre y métodos de uso de ellos
CL2025000292A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos
CO2025002301A2 (es) Anticuerpos anti-ccr8 y métodos de uso
WO2021011673A3 (en) Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
CO2023005044A2 (es) Anticuerpos con capacidad de unirse a ror2 y anticuerpos biespecíficos que se unen a ror2 y cd3
MX2024007288A (es) Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau.
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
AR127898A1 (es) Anticuerpos terapéuticos que se unen al dominio serina·proteasa de masp-2 y usos de estos
CO2025013396A2 (es) Anticuerpos muc1 y cd16a y métodos de uso
CL2018002690A1 (es) Variantes del anticuerpo humanizado ban2401 que se une específicamente a protofibrillas con una vida media serica aumentada composiciones farmacéuticas y usos en el tratamiento del alzheimer y otras enfermedades neurodegenerativas (divisional de la solicitud n° 53-2017).